# Thermo Fisher Scientific Inc.: financial statements, quarterly

TMO · NYSE · CIK 97745 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tmo.md) · [Financials](/companies/tmo/financials.md) · [Filings](/companies/tmo/filings.md) · [Insiders](/companies/tmo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tmo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [10.6](/filings/0000097745-24-000046.md) | [10.9 d](/filings/0000097745-26-000018.md) | [10.3](/filings/0000097745-25-000041.md) | [10.5](/filings/0000097745-25-000101.md) | [10.6](/filings/0000097745-25-000159.md) | [11.4 d](/filings/0000097745-26-000018.md) | [10.4](/filings/0000097745-26-000092.md) | [10.9](/filings/0000097745-26-000144.md) | [11.1](/filings/0000097745-25-000159.md) | [12.2 d](/filings/0000097745-26-000018.md) | [11.0](/filings/0000097745-26-000092.md) | [12.0](/filings/0000097745-26-000144.md) |
| Cost of revenue | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $bn | [0.3](/filings/0000097745-24-000046.md) | [0.3 d](/filings/0000097745-26-000018.md) | [0.3](/filings/0000097745-25-000041.md) | [0.3](/filings/0000097745-25-000101.md) | [0.3](/filings/0000097745-25-000159.md) | [0.4 d](/filings/0000097745-26-000018.md) | [0.3](/filings/0000097745-26-000092.md) | [0.4](/filings/0000097745-26-000144.md) | [0.3](/filings/0000097745-25-000159.md) | [0.4 d](/filings/0000097745-26-000018.md) | [0.3](/filings/0000097745-26-000092.md) | [0.4](/filings/0000097745-26-000144.md) |
| Selling, general and administrative | $bn | [2.0](/filings/0000097745-24-000046.md) | [2.1 d](/filings/0000097745-26-000018.md) | [2.2](/filings/0000097745-25-000041.md) | [2.1](/filings/0000097745-25-000101.md) | [2.1](/filings/0000097745-25-000159.md) | [2.2 d](/filings/0000097745-26-000018.md) | [2.1](/filings/0000097745-26-000092.md) | [2.1](/filings/0000097745-26-000144.md) | [2.2](/filings/0000097745-25-000159.md) | [2.4 d](/filings/0000097745-26-000018.md) | [2.2](/filings/0000097745-26-000092.md) | [2.3](/filings/0000097745-26-000144.md) |
| Operating income | $bn | [1.9](/filings/0000097745-24-000046.md) | [1.9 d](/filings/0000097745-26-000018.md) | [1.7](/filings/0000097745-25-000041.md) | [1.8](/filings/0000097745-25-000101.md) | [1.8](/filings/0000097745-25-000159.md) | [2.0 d](/filings/0000097745-26-000018.md) | [1.7](/filings/0000097745-26-000092.md) | [1.8](/filings/0000097745-26-000144.md) | [1.9](/filings/0000097745-25-000159.md) | [2.3 d](/filings/0000097745-26-000018.md) | [1.9](/filings/0000097745-26-000092.md) | [2.1](/filings/0000097745-26-000144.md) |
| Interest expense | $bn | [0.4](/filings/0000097745-23-000069.md) | [0.4 d](/filings/0000097745-24-000007.md) | [0.4](/filings/0000097745-24-000023.md) | [0.4](/filings/0000097745-25-000101.md) | [0.4](/filings/0000097745-25-000159.md) | [0.3 d](/filings/0000097745-26-000018.md) | [0.3](/filings/0000097745-26-000092.md) | [0.4](/filings/0000097745-25-000101.md) | [0.3](/filings/0000097745-25-000159.md) | [0.4 d](/filings/0000097745-26-000018.md) | [0.4](/filings/0000097745-26-000092.md) | [0.4 d](/filings/0000097745-26-000144.md) |
| Income tax | $bn | [0.1](/filings/0000097745-24-000046.md) | [0.1 d](/filings/0000097745-26-000018.md) | [0.3](/filings/0000097745-25-000041.md) | [0.1](/filings/0000097745-25-000101.md) | [0.1](/filings/0000097745-25-000159.md) | [0.2 d](/filings/0000097745-26-000018.md) | [0.1](/filings/0000097745-26-000092.md) | [0.1](/filings/0000097745-26-000144.md) | [0.2](/filings/0000097745-25-000159.md) | [0.2 d](/filings/0000097745-26-000018.md) | [0.1](/filings/0000097745-26-000092.md) | [0.2](/filings/0000097745-26-000144.md) |
| Net income | $bn | [1.7](/filings/0000097745-24-000046.md) | [1.6 d](/filings/0000097745-26-000018.md) | [1.3](/filings/0000097745-25-000041.md) | [1.5](/filings/0000097745-25-000101.md) | [1.6](/filings/0000097745-25-000159.md) | [1.8 d](/filings/0000097745-26-000018.md) | [1.5](/filings/0000097745-26-000092.md) | [1.6](/filings/0000097745-26-000144.md) | [1.6](/filings/0000097745-25-000159.md) | [2.0 d](/filings/0000097745-26-000018.md) | [1.7](/filings/0000097745-26-000092.md) | [1.7](/filings/0000097745-26-000144.md) |
| Diluted EPS | $ per share | [4.42](/filings/0000097745-24-000046.md) | not reported | [3.46](/filings/0000097745-25-000041.md) | [4.04](/filings/0000097745-25-000101.md) | [4.25](/filings/0000097745-25-000159.md) | not reported | [3.98](/filings/0000097745-26-000092.md) | [4.28](/filings/0000097745-26-000144.md) | [4.27](/filings/0000097745-25-000159.md) | not reported | [4.43](/filings/0000097745-26-000092.md) | [4.68](/filings/0000097745-26-000144.md) |
| Basic EPS | $ per share | [4.44](/filings/0000097745-24-000046.md) | not reported | [3.47](/filings/0000097745-25-000041.md) | [4.05](/filings/0000097745-25-000101.md) | [4.26](/filings/0000097745-25-000159.md) | not reported | [3.99](/filings/0000097745-26-000092.md) | [4.28](/filings/0000097745-26-000144.md) | [4.28](/filings/0000097745-25-000159.md) | not reported | [4.44](/filings/0000097745-26-000092.md) | [4.68](/filings/0000097745-26-000144.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [6.2](/filings/0000097745-23-000069.md) | [8.1](/filings/0000097745-25-000010.md) | [5.5](/filings/0000097745-24-000023.md) | [7.1](/filings/0000097745-24-000040.md) | [4.6](/filings/0000097745-24-000046.md) | [4.0](/filings/0000097745-26-000018.md) | [4.1](/filings/0000097745-25-000041.md) | [4.6](/filings/0000097745-25-000101.md) | [2.0](/filings/0000097745-25-000159.md) | [9.9](/filings/0000097745-26-000144.md) | [3.3](/filings/0000097745-26-000092.md) | [4.1](/filings/0000097745-26-000144.md) |
| Current assets | $bn | [23.1](/filings/0000097745-23-000069.md) | [24.6](/filings/0000097745-25-000010.md) | [23.6](/filings/0000097745-24-000023.md) | [25.5](/filings/0000097745-24-000040.md) | [23.8](/filings/0000097745-24-000046.md) | [22.1](/filings/0000097745-26-000018.md) | [23.4](/filings/0000097745-25-000041.md) | [24.6](/filings/0000097745-25-000101.md) | [22.3](/filings/0000097745-25-000159.md) | [28.7](/filings/0000097745-26-000144.md) | [22.3](/filings/0000097745-26-000092.md) | [23.4](/filings/0000097745-26-000144.md) |
| Total assets | $bn | [97.1](/filings/0000097745-23-000069.md) | [98.7](/filings/0000097745-26-000018.md) | [97.1](/filings/0000097745-25-000041.md) | [98.5](/filings/0000097745-25-000101.md) | [100](/filings/0000097745-25-000159.md) | [97.3](/filings/0000097745-26-000018.md) | [99.0](/filings/0000097745-26-000092.md) | [101](/filings/0000097745-26-000144.md) | [103](/filings/0000097745-25-000159.md) | [110](/filings/0000097745-26-000144.md) | [113](/filings/0000097745-26-000092.md) | [113](/filings/0000097745-26-000144.md) |
| Current liabilities | $bn | [14.2](/filings/0000097745-23-000069.md) | [14.0](/filings/0000097745-25-000010.md) | [13.9](/filings/0000097745-24-000023.md) | [14.8](/filings/0000097745-24-000040.md) | [14.6](/filings/0000097745-24-000046.md) | [13.3](/filings/0000097745-26-000018.md) | [13.2](/filings/0000097745-25-000041.md) | [12.7](/filings/0000097745-25-000101.md) | [14.9](/filings/0000097745-25-000159.md) | [15.2](/filings/0000097745-26-000144.md) | [14.6](/filings/0000097745-26-000092.md) | [15.1](/filings/0000097745-26-000144.md) |
| Long-term debt | $bn | [35.1](/filings/0000097745-23-000069.md) | [34.7](/filings/0000097745-25-000010.md) | [35.4](/filings/0000097745-24-000023.md) | [35.2](/filings/0000097745-24-000040.md) | [35.1](/filings/0000097745-24-000046.md) | [31.1](/filings/0000097745-26-000018.md) | [34.0](/filings/0000097745-25-000041.md) | [35.0](/filings/0000097745-25-000101.md) | [35.5](/filings/0000097745-25-000159.md) | [39.2](/filings/0000097745-26-000144.md) | [42.9](/filings/0000097745-26-000092.md) | [42.3](/filings/0000097745-26-000144.md) |
| Current portion of debt | $bn | [4.8](/filings/0000097745-23-000069.md) | [3.6](/filings/0000097745-25-000010.md) | [4.5](/filings/0000097745-24-000023.md) | [5.1](/filings/0000097745-24-000040.md) | [4.1](/filings/0000097745-24-000046.md) | [2.2](/filings/0000097745-26-000018.md) | [2.8](/filings/0000097745-25-000041.md) | [2.2](/filings/0000097745-25-000101.md) | [3.8](/filings/0000097745-25-000159.md) | [3.5](/filings/0000097745-26-000144.md) | [3.1](/filings/0000097745-26-000092.md) | [3.4](/filings/0000097745-26-000144.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [45.3](/filings/0000097745-23-000069.md) | [46.7](/filings/0000097745-25-000010.md) | [45.5](/filings/0000097745-24-000023.md) | [47.4](/filings/0000097745-24-000040.md) | [49.0](/filings/0000097745-24-000046.md) | [49.6](/filings/0000097745-26-000018.md) | [49.4](/filings/0000097745-25-000041.md) | [50.5](/filings/0000097745-25-000101.md) | [51.0](/filings/0000097745-25-000159.md) | [53.4](/filings/0000097745-26-000144.md) | [51.9](/filings/0000097745-26-000092.md) | [52.7](/filings/0000097745-26-000144.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2,414 d](/filings/0000097745-24-000046.md) | [3,723 d](/filings/0000097745-26-000018.md) | [1,251](/filings/0000097745-25-000041.md) | [1,960 d](/filings/0000097745-25-000101.md) | [2,166 d](/filings/0000097745-25-000159.md) | [3,290 d](/filings/0000097745-26-000018.md) | [723](/filings/0000097745-26-000092.md) | [1,399 d](/filings/0000097745-26-000144.md) | [2,239 d](/filings/0000097745-25-000159.md) | [3,457 d](/filings/0000097745-26-000018.md) | [1,192](/filings/0000097745-26-000092.md) | [2,125 d](/filings/0000097745-26-000144.md) |
| Capital expenditure | $m | [332 d](/filings/0000097745-24-000046.md) | [405 d](/filings/0000097745-26-000018.md) | [347](/filings/0000097745-25-000041.md) | [301 d](/filings/0000097745-25-000101.md) | [272 d](/filings/0000097745-25-000159.md) | [480 d](/filings/0000097745-26-000018.md) | [362](/filings/0000097745-26-000092.md) | [294 d](/filings/0000097745-26-000144.md) | [404 d](/filings/0000097745-25-000159.md) | [465 d](/filings/0000097745-26-000018.md) | [376](/filings/0000097745-26-000092.md) | [450 d](/filings/0000097745-26-000144.md) |
| Dividends paid | $m | [135 d](/filings/0000097745-24-000046.md) | [136 d](/filings/0000097745-26-000018.md) | [135](/filings/0000097745-25-000041.md) | [149 d](/filings/0000097745-25-000101.md) | [150 d](/filings/0000097745-25-000159.md) | [149 d](/filings/0000097745-26-000018.md) | [149](/filings/0000097745-26-000092.md) | [162 d](/filings/0000097745-26-000144.md) | [163 d](/filings/0000097745-25-000159.md) | [162 d](/filings/0000097745-26-000018.md) | [162](/filings/0000097745-26-000092.md) | [175 d](/filings/0000097745-26-000144.md) |
| Share repurchases | $m | [0.0 d](/filings/0000097745-24-000046.md) | [0.0 d](/filings/0000097745-26-000018.md) | [3,000](/filings/0000097745-25-000041.md) | [0.0 d](/filings/0000097745-25-000101.md) | [0.0 d](/filings/0000097745-25-000159.md) | [1,000 d](/filings/0000097745-26-000018.md) | [2,000](/filings/0000097745-26-000092.md) | [0.0 d](/filings/0000097745-26-000144.md) | [963 d](/filings/0000097745-25-000159.md) | [37.0 d](/filings/0000097745-26-000018.md) | [3,000](/filings/0000097745-26-000092.md) | [1,000 d](/filings/0000097745-26-000144.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [395](/filings/0000097745-23-000069.md) | [388](/filings/0000097745-24-000023.md) | [388](/filings/0000097745-24-000040.md) | [388](/filings/0000097745-24-000046.md) | [384](/filings/0000097745-25-000041.md) | [383](/filings/0000097745-25-000101.md) | [384](/filings/0000097745-25-000159.md) | [379](/filings/0000097745-26-000092.md) | [378](/filings/0000097745-26-000144.md) | [378](/filings/0000097745-25-000159.md) | [373](/filings/0000097745-26-000092.md) | [371](/filings/0000097745-26-000144.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 369,747,286 at 2026-06-27, from the cover of the [10-Q filed 2026-07-31](/filings/0000097745-26-000144.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.